Heterogeneity in patient diagnostic pathways: an example from contrast-enhanced ultrasound diagnostic scans for focal liver lesions

BMC Research Notes

Louise M Carr¹  Alexandra Filby¹  Adam B Smith¹ 

[1] York Health Economics Consortium Ltd. University of York, Market Square, Heslington York YO10 5NHUK

关键词: Imaging modalities;    CT;    MR;    Contrast-enhanced ultrasound;   

Others  :  1134076
DOI  :  10.1186/1756-0500-7-199

 received in 2013-07-05, accepted in 2014-03-21,  发布年份 2014

【 摘 要 】

Background

The UK’s National Institute for Health and Care Excellence (NICE) has recommended contrast-enhanced ultrasound (CEUS) for the characterisation of focal liver lesions where the results of standard unenhanced ultrasound are inconclusive. A further recommendation is for CEUS to replace other imaging modalities. However, little is currently known about the diagnostic pathways in the National Health Service (NHS) followed by patients with potential liver lesions. The aim of this study was to identify the diagnostic pathways for a number of representative hospital trusts and record the clinicians’ views on patient experiences of these processes through a series of semi-structured interviews with UK clinicians (radiologists and sonographers) (N = 7). This study was undertaken in the broader context of a larger research project where the overarching research question is focused on patient preferences for CEUS and other imaging modalities, and how these impact on patient quality of life (QOL).

Results

The results from the semi-structured interviews with UK clinicians revealed that there is a great deal of heterogeneity in diagnostic pathways followed by patients with potential liver lesions which differ both within and between hospitals. In terms of the patient experience, the clinicians believed that a combination of the more patient-friendly ultrasound process, and the fact that scan results are given to patients in 80-90% of cases on the day, as well as the problems inherent to other scan modalities (claustrophobia, anxiety) would lead to patients preferring ultrasound compared with other imaging modalities (CT or MR). However, current clinical practice means that patient choice is virtually non-existent.

Conclusions

The significant variation in diagnostic pathways across the NHS will require further standardisation through local agreements if contrast-enhanced ultrasound is to replace other imaging modalities in characterising focal liver lesions in line with NICE Diagnostics Guidance. The gradual development of patient choice of modalities may necessitate a change of practice in radiology processes.

【 授权许可】

   
2014 Smith et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ooi CC, Low SC, Schneider-Kolsky M, Lombardo P, Lim SY, Abu Bakar R, Lo RH: Diagnostic accuracy of contrast-enhanced ultrasound in differentiating benign and malignant focal liver lesions: a retrospective study. J Med Imaging Radiat Oncol 2010, 54(5):421-30.
• [2]Beaton C, Cochlin D, Kumar N: Contrast enhanced ultrasound should be the initial radiological investigation to characterise focal liver lesions. Eur J Surg Oncol 2010, 36(1):43-6.
• [3]Leen E, Angerson WJ, Yarmenitis S, Bongartz G, Blomley M, Del Maschio A, Summaria V, Maresca G, Pezzoli C, Llull JB: Multi-centre clinical study evaluating the efficacy of SonoVue (BR1), a new ultrasound contrast agent in Doppler investigation of focal hepatic lesions. Eur J Radiol 2002, 41(3):200-6.
• [4]Albrecht T, Hohmann J, Oldenburg A, Skrok J, Wolf KJ: Detection and characterisation of liver metastases. Eur Radiol 2004, 14(Suppl 8):P25-33.
• [5]Piscaglia F, Bolondi L, Italian Society for Ultrasound in Medicine and Biology (SIUMB) Study Group on Ultrasound Contrast Agents: The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol 2006, 32(9):1369-75.
• [6]Torzilli G: Adverse effects associated with SonoVue use. Expert Opin Drug Saf 2005, 4(3):399-401.
• [7]National Institute for Health and Clinical Excellence (NICE): SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrastenhanced ultrasound imaging of the liver. NICE Diag Guid 2012., 5NICE
• [8]EnglandMonthlyDiagnosticsData2012–13 http://www.england.nhs.uk/statistics/statisticalwork-areas/diagnostics-waiting-times-and-activity/monthly-diagnostics-waitingtimes-and-activity/monthly-diagnostics-data-2012-13/ webcite. Accessed 01.04.2014